Molecular ontogeny defines three AML subgroups (TP53, secondary, and de novo), each with different clinicopathologic characteristics and distinct response and survival outcomes in patients receiving intensive induction therapy [1, 4, 5]. The gene discussed is TP53; the disease is acute myeloid leukemia.